Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+ T cell infiltration and functional transition

Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+ T cell infiltration and functional transition

Background Immune checkpoint inhibitor (ICI) therapy improves the survival of patients with advanced bladder cancer (BLCA); however, its overall effectiveness is limited, and many patients still develop immunotherapy resistance. The leucine-rich repeat and fibronectin type-III domain-containing prot...

Full description

Bibliographic Details
Main Authors: Xu Chen, Anze Yu, Jiao Hu, Liangmin Fu, Gaowei Huang, Dingshan Deng, Mingxiao Zhang, Yinghan Wang, Guannan Shu, Lanyu Jing, Huihuang Li, Taowei Yang, Jinhuan Wei, Zhenhua Chen, Xiongbing Zu, Junhang Luo
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/10/e007230.full

Internet

https://jitc.bmj.com/content/11/10/e007230.full

Similar Items